Linagliptin does not raise heart risks in diabetes patients

06/26/2013 | Healio

An analysis of 19 double-blind, randomized, controlled trials showed linagliptin did not increase the risk of cardiovascular events and mortality in type 2 diabetes patients. Data showed cardiovascular events occurred at a rate of 60 among those who took once-daily linagliptin compared with 62 in those who took non-linagliptin medications. The results were presented at the ADA 73rd Scientific Sessions.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA